However, anti‐VEGF‐A therapy could be beneficial for patients with psoriasis through a direct effect on both the disease and its systemic sequelae,68, 69, 70 perhaps reducing the risk of psoriasis‐associated vascular events (myocardial infarction and stroke), and cardio‐metabolic diseases (hypertension, diabetes mellitus and metabolic syndrome).71, 72. This evidence concerns the gene VEGFA and metabolic disease.